Hanmi Science Co., Ltd.
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
15
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 7 to 30, 2027 · next Jan 7
- 2 fees due Apr 15 to 20, 2027 · next Apr 15
- 1 fee due May 24, 2027The maintenance fee for Method for purifying human granulocyte-colony stimulating factor from recombinant E. coli (US 9,193,761) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof (US 11,872,283) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,968,316 | Method for the mass production of immunoglobulin Fc region deleted initial methionine residues In force · From the USPTO record | In force | From the USPTO record | |
| US 8,124,094 | Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 8,513,426 | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same In force · From the USPTO record | In force | From the USPTO record | |
| US 7,888,511 | Method of preparing esomeprazole and salts thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,476,230 | Insulinotropic complex using an immunoglobulin fragment In force · From the USPTO record | In force | From the USPTO record | |
| US 8,188,102 | Amide derivative for inhibiting the growth of cancer cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,263,084 | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate In force · From the USPTO record | In force | From the USPTO record | |
| US 9,161,933 | Solid Pharmaceutical Composition Comprising Amlodipine and Losartan and Process for Producing Same In force · High confidence | In force | High confidence | |
| US 9,422,349 | N-Terminal Modified EXENDIN-4 In force · Medium confidence | In force | Medium confidence | |
| US D723,564 | RFID reader In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 45: 3 patents in force now held by others · 37 lapsed for an unpaid fee · 17 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 13 no status recorded